These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1311 related articles for article (PubMed ID: 28813417)

  • 1. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.
    Burr ML; Sparbier CE; Chan YC; Williamson JC; Woods K; Beavis PA; Lam EYN; Henderson MA; Bell CC; Stolzenburg S; Gilan O; Bloor S; Noori T; Morgens DW; Bassik MC; Neeson PJ; Behren A; Darcy PK; Dawson SJ; Voskoboinik I; Trapani JA; Cebon J; Lehner PJ; Dawson MA
    Nature; 2017 Sep; 549(7670):101-105. PubMed ID: 28813417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMTM6, a potential immunotherapy target.
    Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.
    Mezzadra R; Sun C; Jae LT; Gomez-Eerland R; de Vries E; Wu W; Logtenberg MEW; Slagter M; Rozeman EA; Hofland I; Broeks A; Horlings HM; Wessels LFA; Blank CU; Xiao Y; Heck AJR; Borst J; Brummelkamp TR; Schumacher TNM
    Nature; 2017 Sep; 549(7670):106-110. PubMed ID: 28813410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation.
    Xu X; Xie T; Zhou M; Sun Y; Wang F; Tian Y; Chen Z; Xie Y; Wu R; Cen X; Zhou J; Hou T; Zhang L; Huang C; Zhao Q; Wang D; Xia H
    Nat Commun; 2024 May; 15(1):4237. PubMed ID: 38762492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody.
    Jia XM; Long YR; Yu XL; Chen RQ; Gong LK; Geng Y
    Acta Pharmacol Sin; 2023 May; 44(5):1095-1104. PubMed ID: 36418428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.
    Miao B; Hu Z; Mezzadra R; Hoeijmakers L; Fauster A; Du S; Yang Z; Sator-Schmitt M; Engel H; Li X; Broderick C; Jin G; Gomez-Eerland R; Rozeman L; Lei X; Matsuo H; Yang C; Hofland I; Peters D; Broeks A; Laport E; Fitz A; Zhao X; Mahmoud MAA; Ma X; Sander S; Liu HK; Cui G; Gan Y; Wu W; Xiao Y; Heck AJR; Guan W; Lowe SW; Horlings HM; Wang C; Brummelkamp TR; Blank CU; Schumacher TNM; Sun C
    Cancer Cell; 2023 Oct; 41(10):1817-1828.e9. PubMed ID: 37683639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.
    Zhang J; Bu X; Wang H; Zhu Y; Geng Y; Nihira NT; Tan Y; Ci Y; Wu F; Dai X; Guo J; Huang YH; Fan C; Ren S; Sun Y; Freeman GJ; Sicinski P; Wei W
    Nature; 2018 Jan; 553(7686):91-95. PubMed ID: 29160310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
    Zugazagoitia J; Liu Y; Toki M; McGuire J; Ahmed FS; Henick BS; Gupta R; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
    J Thorac Oncol; 2019 Dec; 14(12):2084-2096. PubMed ID: 31605795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer.
    Liu Y; Li X; Zhang H; Zhang M; Wei Y
    Oncogene; 2021 Mar; 40(12):2230-2242. PubMed ID: 33649535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner.
    Long Y; Chen R; Yu X; Tong Y; Peng X; Li F; Hu C; Sun J; Gong L
    Cancer Immunol Res; 2023 Feb; 11(2):241-260. PubMed ID: 36484740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
    Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
    Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
    Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity.
    Ren Y; Qian Y; Ai L; Xie Y; Gao Y; Zhuang Z; Chen J; Chen YX; Fang JY
    Nat Commun; 2021 Sep; 12(1):5405. PubMed ID: 34518538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.
    Yao H; Lan J; Li C; Shi H; Brosseau JP; Wang H; Lu H; Fang C; Zhang Y; Liang L; Zhou X; Wang C; Xue Y; Cui Y; Xu J
    Nat Biomed Eng; 2019 Apr; 3(4):306-317. PubMed ID: 30952982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma.
    Liu LL; Zhang SW; Chao X; Wang CH; Yang X; Zhang XK; Wen YL; Yun JP; Luo RZ
    Cancer Immunol Immunother; 2021 Feb; 70(2):417-429. PubMed ID: 32770259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
    Chen J; Jiang CC; Jin L; Zhang XD
    Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma.
    Chen L; Yang QC; Li YC; Yang LL; Liu JF; Li H; Xiao Y; Bu LL; Zhang WF; Sun ZJ
    Cancer Immunol Res; 2020 Feb; 8(2):179-191. PubMed ID: 31771985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
    Tu X; Qin B; Zhang Y; Zhang C; Kahila M; Nowsheen S; Yin P; Yuan J; Pei H; Li H; Yu J; Song Z; Zhou Q; Zhao F; Liu J; Zhang C; Dong H; Mutter RW; Lou Z
    Mol Cell; 2019 Jun; 74(6):1215-1226.e4. PubMed ID: 31053471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
    Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
    Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.